



20
22

FROM MOBILIZATION TO IMPACT: MONTRÉAL INVIVO,
AT THE HEART OF A VIBRANT ECOSYSTEM

MONTRÉAL
INVIVO 

TABLE OF CONTENTS

Messages from our leadership – chief executive officer and chairman of the board of directors	3
Life sciences and health technologies sector profile	4
Who we are? Positioning Mission Mandate Our actions	5
Axes of intervention and strategic priorities	6
Montréal invivo: strategic actions for a strong impact	7
Stay tuned	15
Effervescence 2022	21
Visibility	23
Mobilization	26
Decision-makers	28
Our team	29
Our allies	32

MESSAGES FROM OUR LEADERSHIP



Martin Leblanc

Co-founder and Vice-Chairman of the Board of Directors of CellCarta Biosciences and Chairman of the Board of Directors of Montréal InVivo



Frank Béraud

Chief Executive Officer of Montréal InVivo

2022 marks the year we finally emerge from the pandemic in terms of an acute situation! It is the year that we return to a certain normalcy in the activities carried out within the ecosystem. As we look back on the year 2022, there are three themes that particularly stood out for us. The first is the issue of health data, which dominated our concerns at the beginning and then at the end of the year with the introduction of Bill 19 and then its replacement by Bill 3. Access to data is a major issue for the sector, particularly regarding research and innovation. We all know that the strength and progress of life sciences in Quebec are intimately linked to fluid, ethical and secure access to quality data. This issue will continue to keep us busy throughout the year 2023.

The second important point for us was the very successful launch of the new version of the Québec Life Sciences Strategy (QLSS) at the close of the EFFERVESCENCE event by Minister Fitzgibbon. This update of the QLSS came at the right time to take into account the changes in our environment after two years of pandemic. Once again, the government's involvement and mobilization of key sector stakeholders in this development process is a true benchmark in the creation of public policy.

The third aspect is more internal to Montréal InVivo as 2022 marked the mid-point of the organization's strategic plan. It was therefore an opportunity to analyze what is working well, what can be improved upon and what is missing in the cluster's portfolio of activities and projects. The team was attentive and learned from this first half of the four-year strategic plan. In particular, it emerged that adjustments will have to be made in 2023 to the project committees so as not to lose what was one of the distinctive features of Montréal InVivo's projects: a space for reflection on the sector's issues, a think tank that fueled the genesis of the cluster's projects. Announcements will be made shortly to address this need.

Finally, it is important for us to highlight the phenomenal work accomplished by the Montréal InVivo team. This team, which is constantly growing and changing, is always ready to take on new challenges, undertake new projects, and explore new avenues, such as those related to citizen acceptability or biomanufacturing.

Thank you everyone! And thank you to the many volunteers who are involved in the committees and other activities of the cluster.



INDUSTRY SNAPSHOT


LIFE SCIENCES AND HEALTH TECHNOLOGIES

HIGHLIGHTS OF QUEBEC'S LIFE SCIENCES AND

HEALTH TECHNOLOGIES SECTOR

Quebec between **2018** and **2021**

Ranked **10th** in North America in terms of employment intensity with **1.2%**




Went from **12th** to **11th** place in terms of jobs in North America, with **46 883** LSHT jobs in 2021

Annual job growth rate of **5.6 %**



4th largest percentage increase in employment in North America



WHO WE ARE?



POSITIONING

Since its creation, Montréal InVivo has been central to the life sciences and health technologies (LSHT) ecosystem. We are known for our mobilizing strength, our voice as a privileged independent interlocutor for the public sector, as well as our ability to initiate and lead impactful projects for the development of the sector.



VISION

Standing out through an innovative, collaborative and sustainable life sciences and health technologies ecosystem.



MISSION

Montréal InVivo is a network that facilitates discussion, mobilization and collaboration within the LSHT ecosystem. We provide unifying leadership of all stakeholders in the Greater Montréal area to strengthen the sector's growth, competitiveness and outreach.

OUR ACTIONS

- Studies and analyses (business intelligence)
- Mobilization and networking
- Impactful projects
- Support for businesses and entrepreneurship
- Outreach

AREAS OF INTERVENTION

AND STRATEGIC PRIORITIES

RESEARCH AND INNOVATION AXIS

Making a significant contribution to the adoption of innovations in LSHT in Quebec is a priority for Montréal InVivo. Through the Research and Innovation axis, our organization supports and promotes initiatives aimed at stimulating the development and adoption of innovations in the Quebec health network.

TALENT AXIS

In recent years, several projects have been initiated by Montréal InVivo with the goal of actively attracting a qualified, sufficiently substantial workforce to support the needs of the LSHT sector. Through a diversification of our communication practices, which allows us to better promote careers and the LSHT sector to the next generation, we seek to improve, raise awareness and integrate the pool of expertise and talent in the sector.

ENTREPRISES AXIS

The priority of action of Montréal InVivo’s Enterprises axis is to create, develop and grow businesses in the sector. At the strategic level, we focus on capacity building and on developing an original service offer to better equip and support entrepreneurs.

POSITIONING AXIS

Since its inception, Montréal InVivo has worked continuously to demonstrate the leading role of the LSHT sector in Greater Montréal and Quebec. Our strategy includes working with non-industry players working to increase productivity and technology commercialization to collaboratively develop a dedicated offering for the LSHT sector.

CITIZEN ACCEPTABILITY AXIS

The commitment to integrate and raise awareness among citizens of the impacts of innovation in LSHT in Quebec is becoming a priority for our sector. Through the citizen acceptability axis, we seek to pursue our efforts to raise awareness and involve citizens to promote the development of the sector.

STRATEGIC ACTIONS

FOR A POWERFUL IMPACT

The year 2022 is marked by the unveiling of several impactful government strategies and action plans, including the Québec Life Sciences Strategy, the Québec Strategy to Support Research and Investment in Innovation, the government action plan on entrepreneurship (Plan d'action gouvernemental en entrepreneuriat (PAGE)) and the Quebec Policy for Rare Diseases.

Montréal InVivo has acted on this opportunity to solidify its service offering to organizations in the sector and to develop strategic partnerships in order to better meet the needs of the

LSHT sector and help it achieve the ambitious objectives set by our various levels of government.

LSHT companies, in particular, need support in terms of expertise, access to specialized equipment, affordable work spaces and financing throughout their life cycle. Montréal InVivo is also positioning itself to support research and innovation by facilitating collaboration and linkages between different stakeholders as well as the public acceptance of the initiatives developed. To support the sector's vitality, we also act to develop the skills of a diversified

and inclusive labour pool. Finally, the cluster guides, measures and monitors performance indicators for the sector by conducting studies and analyses that will allow us to showcase the successes of our ecosystem and to find sustainable solutions to our challenges together.

1

RARE DISEASES

MANDATE

1. Enable Quebec patients suffering from a rare disease to have rapid and optimal access to therapeutic and diagnostic innovations.
2. Improve the competitiveness of Quebec's innovation ecosystem to attract investment and develop our skills by drawing on international best practices.

ACHIEVEMENTS

The launch of Montréal InVivo's Strategic Plan on Rare Diseases in April 2022 and its presentation to the participants of the EFFERVESCENCE event in May are two important achievements resulting from this project committee.

Following the publication by the Ministère de la Santé et des Services sociaux (MSSS) of the Quebec Policy for Rare Diseases in June 2022, a consultation was also conducted with members of the project

committee and other stakeholders to identify several initiatives that are already in place and to recommend targets, indicators of success and concrete actions to be implemented as part of the governmental action plan for rare diseases being developed by the MSSS.

Stakeholder engagement continued in the fall to lay the groundwork for a strategic intelligence tool on new therapies indicated for the treatment of rare conditions to continue to support the community in 2023.

2

INTEGRATION OF INNOVATIONS IN HEALTH TRAJECTORIES

MANDATE

Support the integration and adoption of innovations into care pathways while promoting knowledge sharing across the continuum of care to the patient's home.

ACHIEVEMENTS

By creating the project committee on the integration of innovations, Montréal InVivo has encouraged collaboration between the working group representing health innovation stakeholders and other stakeholders such as the MSSS Bureau de l'innovation, with the aim of proposing concrete actions to support the scaling up of innovations in health care institutions and to catalyze collaboration between innovators and the clinical community.

In 2022, Montréal InVivo participated in the consolidation of several ministerial initiatives and the implementation of measures announced in government strategies, notably through collaboration with the MSSS Bureau de l'innovation to help them develop their tools for entrepreneurs. We have also initiated a reflection on the preparation of the Quebec health system for the arrival of innovations in the treatment and diagnosis of neurocognitive disorders.

Proposals and implementation of pragmatic solutions to this issue will continue in 2023.

3

CONTINUUM

Skills management and development

MANDATE

Matching the needs of a booming job market with candidates requiring additional training and practical experience to ensure proper integration and retention in the data sciences sector.

ACHIEVEMENTS

The year 2022 was marked by the completion of the *Continuum* project, which came into being in 2020 with funding from the Conseil emploi métropole (CEM). The project proposed to combine high-level training in collaboration with educational institutions and practical training in the form of mentoring in companies carried out by the Computer Research Institute of Montréal (CRIM).

Through this initiative, 32 key data science competencies were profiled, nine candidates completed projects within companies, and three of them subsequently obtained permanent employment.

For the *Continuum* project, 2022 symbolizes the end of the two-year pilot project, the extension of the project thanks to a second financing that allows us to target bio-economy companies across Quebec, and ultimately, a great source of pride for the Montréal InVivo team!

4

STUDIES ON THE ECONOMIC INDICATORS OF THE LSHT SECTOR

MANDATE

This project aims to update a study on key indicators of the sector in terms of employment and economic value of the innovation chain.

ACHIEVEMENTS

The first part of this study was an opportunity to compare the LSHT sector in Quebec to several Canadian and American jurisdictions on the number of employees, the variation in employment and the employment intensity according to the different sub-sectors.

This project has highlighted the relative increases in Quebec's employment ranking in the LSHT sector and the many changes brought about by the

pandemic. The economic value of the innovation chain is currently being studied and will determine the percentage of Quebec's gross domestic product represented by the LSHT sector.

EVER-INCREASING SUPPORT FOR COMPANIES

ACCÉLÉRACTION EXPERT COMMITTEES

In 2022, Montréal InVivo had the opportunity to strengthen its support to companies through the implementation of an *AccélérAction* expert committee tailored to the MISO Chip start-up, active in drug development and personalized medicine in oncology. This committee brought great added value to the company thanks to the advice of targeted experts in their field of activity.

« The generosity of the members and Montréal InVivo allowed us to have an external perspective and advice on the company's corporate presentation and strategy. We came away with answers to our questions and new hypotheses to test with investors. »

- Testimonial of MISO Chip

MOMENTUM

Since 2022, Montréal Invivo has qualified as a relay organization for the Momentum program of the Mouvement des accélérateurs d'innovation du Québec (MAIN) which allows innovative life sciences start-ups with high growth potential to benefit from a customized support program. This program provides expert services up to a maximum of \$75,000 to accelerate the company's development and move it more quickly to the commercialization phase.

« The Momentum program and the support of Montréal InVivo has provided Jenthera with access to top quality consultants to develop its regulatory and business strategy for its Series A financing. »

- Testimonial of Jenthera Therapeutics, Inc.

SME OFFENSIVE

Montréal InVivo's support for companies in 2022 is reflected in the launch of the *SME offensive strategy project*. The goal was to (re)connect with small and medium-sized enterprises (SMEs) in the sector in order to better understand their needs and guide our actions and collaborations in this direction. Through this initiative, the team met with more than 60 companies that were not totally familiar with Montréal InVivo's mission and the cluster's tools and services in order to help them in their business development and to mobilize new participants to our project committees.

Our mobilization efforts will continue in 2023, in collaboration with other ecosystem partners.

DIRECTORY OF COLLABORATIVE RESEARCH PLATFORMS

In 2022, we put a directory of academic research platforms online on the Montréal InVivo website in order to give them visibility and to foster collaborations with companies in the LSHT sector. We contacted the academic research platforms of the sector in Montreal, 104 of which agreed to appear in the directory, which is organized by the platforms' areas of expertise and is included in the toolbox of our website. We also began discussions in 2022 to identify affordable workspaces for start-ups in the sector, a process that will continue through 2023.



OPPORTUNITIES FOR CELEBRATION

BIOSUCCÈS

The year 2022 was marked by the celebration of the 10th anniversary of Biosuccès, a Quebec-wide mentoring network dedicated to entrepreneurs in the LSHT sector. For a decade now, this network has considerably strengthened the ecosystem supporting entrepreneurship in the sector. With 19 active dyads in our network and the recruitment of three new mentors, the mentoring process allows a diversity of entrepreneurs to increase their chances of success and develop their companies.



LIFE SCIENCES ENTREPRENEURSHIP DEVELOPMENT PROGRAM

In 2022, the *Life Sciences Entrepreneurship Development Program (LSEDP)*, created through collaboration between Montréal InVivo, the Faculty of Pharmacy at Université de Montréal and Concordia University's John Molson Executive Centre, celebrated its fifth anniversary! After five cohorts and 87 participants, this project, whose objective is to strengthen the entrepreneurial skills of LSHT leaders, will be continued in 2023, thanks to a NovaScience grant awarded by the Ministère de l'Économie, de l'Innovation et de l'Énergie (MEIE) to support the next generation. A fine example of the multidisciplinary nature of our projects, which combines the Enterprises and Talent axes in a single initiative.

STAY TUNED

FOR OUR PROJECT COMMITTEES!

For more than two years now, project committees, made up of professionals working in the life sciences and health technologies sector, have been an integral part of Montréal InVivo's organizational model. Our project committees provide a forum for in-depth reflection on issues in the sector with the goal of actively working on specific, impactful projects. From research institutes, to funding and support organizations, to various levels of government and companies from multiple backgrounds, the diversity and multidisciplinary nature of the professionals who form our project committees are among our greatest strengths.

In addition to the projects mentioned above (pages 8-11), the year 2022 has seen the birth and evolution of other committees and projects that are important to our ecosystem across all of our areas of intervention. The next few pages provide an overview of some of them, for which major benefits are expected in 2023... Stay tuned!

PROJECT COMMITTEE

Agreements based on
the value of innovations

MANDATE : Facilitate innovative reimbursement arrangements based on the value of therapeutic innovations.

ACHIEVEMENTS : In collaboration with the Quebec Cancer Coalition and several other stakeholders, the Montréal InVivo working group is intent on developing a demonstration project aimed at generating an opportunity to learn about the operationalization of this type of agreement. The pillars of this project will be developed in 2023.

PROJECT COMMITTEE

Innovations in the
treatment and
diagnosis of
neurocognitive
disorders

MANDATE : Help the health care system be better prepared for upcoming innovations that have the potential to change the course of disease, by encouraging integration of innovative technologies and practices in the care trajectories.

ACHIEVEMENTS : This three-phase project will provide a deeper understanding of the barriers to early identification of mild neurocognitive disorders in the Quebec context, propose innovative solutions to increase early identification, and aim to evaluate the value of these solutions in real care settings. The next steps in the initiative will include conducting a survey on health professionals' perception of early detection.

PROJECT COMMITTEE

e-IMPAQc
immunotherapy

MANDATE : Support the integration of an innovation that engages patients in their care trajectories and provides them with the tools so they can effectively communicate their health outcomes to their communities.

ACHIEVEMENTS : Patients, clinicians and researchers have worked together to adapt the e-IMPAQc program to meet the needs of patients receiving immune checkpoint inhibitor therapy and to plan a change in practice at participating sites, beginning in 2023.

PROJECT COMMITTEE

Manpower in
biomanufacturing

MANDATE : Bring together players and initiatives to promote the development of expertise in biomanufacturing in Quebec and avoid dispersing efforts.

ACHIEVEMENTS : At the project committee in March 2022, our team presented a map of the biology training available in Quebec and produced a draft of qualifying courses in biomanufacturing.

PROJECT COMMITTEE

Mobilizing the next
generation of LSHT
professionals

MANDATE : Create activities and projects to boost knowledge of sectors, careers and available job opportunities.

ACHIEVEMENTS : In 2022, Montréal InVivo continued to support PharmaBio Développement by implementing several networking activities to address the considerable lack of opportunities for candidates and professionals to meet and interact in the labour market, providing support that will continue in 2023.

PROJECT COMMITTEE

Skills management
and development

MANDATE : Provide a tool to facilitate the migration of SMEs to a successful talent management culture.

ACHIEVEMENTS : In 2022, 7 SMEs from the LSHT sector were able to benefit from the Compétences PME program while the major trends in human resources management by sector will be presented by a consultant in 2023.

PROJECT COMMITTEE
[AI & health podcasts](#)

MANDATE : Inform and train healthcare entrepreneurs and intrapreneurs on the challenges of healthcare and artificial intelligence.

ACHIEVEMENTS : This French-language training podcast on AI in health was developed in 2022, in partnership with Humaniteq and the CHUM's École d'intelligence artificielle en santé (ÉIAS). The 3 series of 4 episodes, each with a specific level of knowledge, will be aired in 2023.

PROJECT COMMITTEE
[EDI \(equity, diversity and inclusion\)](#)

MANDATE : Raise awareness in the sector of the level of equity, diversity and inclusion (EDI) now and in the future.

ACHIEVEMENTS : At EFFERVESCENCE, a session moderated by Women in Bio and funded by Ville de Montréal focused on the place of women on boards of directors. At the event, training on neurodiversity in work teams and training on EDI offered by IVADO were also offered. Montréal InVivo will also represent Quebec in the IDEA project initiated in 2022 by Life Sciences Ontario (LSO) in collaboration with adMare, Pfizer and Shift Health. The initiative aims to take stock of the state of EDI in Quebec in the life sciences through 3 focus groups and will include members of the EDI project committee.

BILL 19
 Access to health information

MANDATE : Illustrate the impact of Bill 19 on organizations in the LSHT sector.

ACHIEVEMENTS : In the winter of 2022, Montréal InVivo collaborated with Forum IA Québec on a consultation with AI-health companies to gain a better understanding of the impact of the new Bill 19 on their activities, following which a report was submitted to the MSSS. Broader consultations were also conducted in the fall of 2022 to better identify the issues related to Bill 3 and to continue the work in 2023.



Agreements based on the value of innovations

Alain Couture
GSK

Allison Wills
20Sense

Benoit Tousignant
Novo Nordisk

Donald Allard
Bristol Meyers Squibb

Eva Villalba
Coalition Priorité Cancer Québec

France Migneault
Gilead

François Laflamme
IQVIA

Geneviève Pelletier
Quebec Association of Proprietor Pharmacists

Geneviève Plamondon
Institut national d'excellence en santé et en services sociaux (INESSS)

Hasna Rouighi
Ministère de la Santé et des services sociaux du Québec

Isabelle Gagnon
AstraZeneca

Jean Jutras
AstraZeneca

Jean Lachaine
Université de Montréal

Jean-Luc Fortier
AbbVie

Julie Couture
Ministère de la Santé et des Services sociaux du Québec

Julie Gauthier
Amgen

Keith Woolrich
McGill University Health Centre

Natalie Verreault
Roche

Ranya El Masri
GSK

Stéphane Barakat
AbbVie

Stéphanie Lacroix
Merck

Sylvie Baril
Janssen

Sylvain Clermont
Incyte

Thérèse Gagnon-Kugler
Vertex Pharmaceuticals Inc.

Valérie Guillot
Ministère de la Santé et des services sociaux du Québec

Vincent Raymond
Pfizer

Innovations in the treatment and diagnosis of neurocognitive disorders (NCDs)

Agnès Xenopoulos
Eli Lilly Canada

Anne-Marie Rivard
Roche

Antonin Caron
Roche

Geneviève Tousignant
Eisai

Geneviève Pelletier
Quebec Association of Proprietor Pharmacists

Isabelle Girard
Plakett Services Cliniques

Louis Verret
Neurologist - Clinique inter-disciplinaire de mémoire du CHU de Québec (CIME)

Nicolas Beaudet
Omnimed

Nouha Ben Gaied
Federation of Quebec Alzheimer Societies

Sabrina Fettal
MEDTEQ+

Yves Couturier
Réseau 1 Québec

Ziad Nasreddine
Institut et Clinique MOCA

Integration of innovations into care trajectories

Alain Couture
GSK

Antonin Caron
Roche

Anne-Marie Rivard
Roche

Danielle Routhier
Ministère de la santé et des services sociaux du Québec

François Bergeron
MEDTEQ+

Geneviève Pelletier
Quebec Association of Proprietor Pharmacists

Geneviève Plamondon
Institut national d'excellence en santé et en services sociaux (INESSS)

Hasna Rouighi
Ministère de la Santé et des services sociaux du Québec

Isabelle Girard
Plakett Clinical Services

Mélanie Caron
Institut national d'excellence en santé et en services sociaux (INESSS)

Mylène Levesque
Unité de soutien SSA Québec

Nicolas Beaudet
Omnimed

Sylvain Bussière
Biogen

Tarek Bouhali
Réseau 1 Québec

Yves Couturier
Réseau 1 Québec

Sabrina Fettal
MEDTEQ+

Valérie Guillot
Ministère de la Santé et des services sociaux du Québec

AI & health podcast

Alejandro Rodriguez Aguirre
Centre hospitalier de l'Université de Montréal

Christian Blouin
Patient partenaire

Fares Antaki
Université de Montréal

Jessica Forcillo
Centre hospitalier de l'Université de Montréal

Julie Grégoire
Centre hospitalier de
l'Université de Montréal

Mariem Abid
Centre hospitalier de
l'Université de Montréal

Marie-Paule Jeansonne
Forum IA Québec

Mikael Lemelin Brisebois
Centre hospitalier de
l'Université de Montréal

Oriane Morriet
Humaniteq

Sarah Gagnon-Turcotte
Conseil de l'innovation
du Québec

Steve Labbé
Ministère de la Santé et des
Services sociaux du Québec

Therence Bois
Valence Discovery

Rare diseases

Angela Genge
McGill University

Anita Burgun
Université de Sherbrooke

Casandra Poitras
Association de la

Neurofibromatose du
Québec

Cyril Bories
Ministère de la Santé et des
Services sociaux du Québec

Denis Laflamme
Takeda

Diana Iglesias
Genome Québec

Diane Brisson
Ecogène-21

Dominique Grenier
AstraZeneca

Donald Vinh
McGill University

Hélène Vidot-Delerue
Université du Québec à
Montréal

Hermance Beaud
Université du Québec à
Montréal

Jacques Michaud
CHU Ste-Justine

Julie Couture
Ministère de la Santé et des
Services sociaux du Québec

Jonathan Pratt
Regroupement québécois
des maladies orphelines

Liliana Polcari
Biogen

Marie-Claude Battista
Université de Sherbrooke

Marie-Hélène Bolduc
Muscular Dystrophy
Canada

Mélanie Langelier
McGill University Health
Centre

Nathalie Girard
Ministère de l'Économie,
de l'Innovation et de
l'Énergie

Nicolas Pilon
Université du Québec à
Montréal

Olivier Jérôme
Catalis Québec

Roxanne Dault
Université de Sherbrooke

Vincent Mooser
McGill University

Vincent Raymond
Pfizer

Thérèse Gagnon-Kugler
Vertex Pharmaceuticals Inc.

Continuum

Élisabeth Droz
Pharmabio Développement

Fanny Leroux
Computer Research
Institute of Montréal (CRIM)

France Dussault
Qualifications Québec

**Marie-Pierre Ouellet
Morand**
Collège Ahuntsic

Nathalie Leblanc
Qualifications Québec

Nathalie Parent
Université de Montréal

Ricardo Acevedo
Qualifications Québec

Virginie Chartrand
Collège Ahuntsic

Skills-SME

Béatrice Perier Agostini
AéroMontréal

Catherine Lavoie
Montréal Metropolitan
Community (CMM)

David Lampron
Équipe Humania

Julie Poirier
Conseil emploi métropole

Martin Hamel
GORD Associates
Consulting

Mélanie Lussier
Propulsion Québec

Sylvain Giguère
Montréal Metropolitan
Community (CMM)

Next Generation InVivo

Amaury Piveteau
Montréal International

Célia Jacobberger-Foissac
CHUM Research Centre
(CRCHUM)

Claire Edrington
McGill University

Cynthia Kwan
McGill University

Michelle Savoie
Université de Montréal

Moushumi Nath
McGill University

Prisca Bustamante
McGill University

Romane Oliverio
Polytechnique Montréal

Thomas Milan
Institute for Research in
Immunology and Cancer
(IRIC)

Tina Gruosso
Advanced Accelerator
Applications

**Manpower in
biomanufacturing**

Amine Kamen
McGill University

Arianne Trudeau
Médicament Québec

Armand Soldera
Université de Sherbrooke

Brigitte St-Denis
Ministère de l'Économie,
de l'Innovation et de
l'Énergie



Carmen Nazar
Cégep Gérald Godin

Christina Aon
Centre d'expertise et de
recherche appliquée en
sciences pharmaceutiques
(CERASP)

Corinne Guenette
Innovation, Science and
Economic Development
Canada

Corinne Hoesli
McGill University

Daniel Ndong
Bausch Health

Denis DeBlois
Université de Montréal

Éric Athlan
Collège Ahuntsic

Frédéric Leduc
Immune Biosolutions

Gregory de Crescenzo
Polytechnique Montréal

Jean-Simon Blais
KABS

Julie Patenaude
Grifols

Joanne Jordan
BioTalent Canada

Karine Souffrez
Institut national de la
recherche scientifique

Kim Bourgeois
Pharmabio Développement

Manon Couture
Université Laval

Marie-Claude Battista
Université de Sherbrooke

Marc Servant
Université de Montréal

Michel Fafard
Cégep Gérald-Godin

Mounia Azzi
AdMare BioInnovations

Nadia Dubé
Investissement Québec

Nawel Bailey-Rojkjaer
SmokePond Biologics

Patrick Daoust
CASTL

Penny Walsh-McGuire
CASTL

Richard Ares
Université de Sherbrooke

Richard Grégoire
Teva Canada

Sébastien Sabbagh
Montreal Clinical Research
Institute (IRCM)

Sophie Lerouge
ÉTS Montréal

Vanessa Laflamme
CellCAN

Vincent Dodelet
CNRC

Entrepreneurship InVivo

Alain Bakayoko
PME Montréal

Alexandre Duval
Innovation, Science and
Economic Development
Canada

**Christele Berthelot-
Logsdon**
Catalyste Technologies
Santé (CTS)

Christophe Manhes
Québec Vitae

Ferdaous Dorai
CeUMontréal

François Ravenelle
Inversago

Gad Sabbatier
Axelys

Inès Holzbaur
Amorchem

James Doyle
Modelis

Laurent Ziri
Jenthera

Mali Prud'homme
SAGE Innovation

Marie-Pierre Cossette
Fonds de Recherche
Québec

Nada Zogheib
CeUMontréal

Naouel Hanani
Startup Montréal

Noémie Simon
MAIN

Pamela Champagne
District 3

Pamela Champagne
District 3

Pierre Falardeau
Pharm-Asset, Inc.

Rabih Kyriakos
AdMare Bioinnovations

Vanessa Marsan
Ministère de l'Économie, de
l'Innovation et de l'Énergie

**Equity, Diversity, Inclusion
(EDI)**

Anne No-Delaide
RBC Royal Bank

Christine Lennon
Incyte

Diane Côté
MEDTEQ+

Dominique Michaud
Concordia University

Inès Holzbaur
Amorchem

Jennifer Chan
Merck

Joanie Fournier
Diex Recherche

Julie Mantovani
Université de Montréal

Laurence Rulleau
CTI Life Sciences


Mariève Blanchet
Université du Québec à
Montréal

Michelle Savoie
Université de Montréal

Nadia Di Chiara
Fonds FTQ

Neila Kaou
Polytechnique Montréal

Sarah Jenna
MIMs




EFFERVESCENCE

THE FUTURE
OF LIFE
SCIENCES

On May 10, 11 and 12, 2022, more than 588 people went to the Marché Bonsecours in Montréal for the third edition of EFFERVESCENCE. After two long years of pandemic, this flagship life sciences event in Quebec was held in person and proved to be a great success! The third edition of EFFERVESCENCE brought together 17 partners whose fruitful collaboration allowed for the implementation of a multidisciplinary and innovative program of the LSHT sector, marked by candid, enriching discussions between scientists, entrepreneurs, students, investors and professionals in the sector. The event also served as a platform for the unveiling of the Québec Life Sciences Strategy by Minister Pierre Fitzgibbon.

The 2022 programming promoted collaboration and networking between various industry players, offering many opportunities to forge business relationships, meet new people, participate in inspiring conferences and discover what's new in Quebec's LSHT sector.



The broad diversity in the general profile of the attending the third edition of **EFFERVESCENCE** greatly contributed to the success of the event in 2022 !



CONTEST

TELL US ABOUT YOUR RESEARCH IN 180 SECONDS

The 2022 edition of EFFERVESCENCE highlighted young professionals of the next generation of scientists who value scientific popularization skills, through the “Tell us about your research in 180 seconds” Contest. Out of 37 applications, the 10 finalists from bachelor to post-doctorate level, were able to present their research project for 3 minutes on the Pitch Stage. This contest, which was made possible thanks to the support of PharmaBio Développement, VisTaScience and Montréal InVivo, brought out four winners: Rebecca Cusseddu, winner of the Gold Award, Gabriel Blanco Gomez, winner of the Silver Award, and Namasthée Harris-Gauthier and Jade Latraverse-Arquilla, winners of the Bronze Award.

CONTEST


EFFERVESCENCE STARS CONTEST

The second edition of the EFFERVESCENCE Stars Contest rewarded three young Quebec researchers whose scientific contribution and recent collaboration with the LSHT sector have been remarkable. As part of this competition, a jury composed of six members of the ecosystem elected three winners out of 10 applications received, namely Marina Martinez, Ahmad Haidar and Andrés Finzi. Prizes of \$1,000 per winner were presented by Gilead, contest sponsor, and awarded by the 2021 winners to the 2022 winners.

CONTEST

PAN-CANADIAN START-UP PITCH COMPETITION

For a second year, 10 LSHT start-ups from across Canada were showcased at EFFERVESCENCE through the Pan-Canadian Start-up Pitch Competition, with the following start-ups from across Canada qualifying as finalists: HDAX Therapeutics, NeuroServo, FemTherapeutics Inc, Ditch Labs, Paperplane Therapeutics, Targa Biomedical, Axolotl Biosciences, MISO Chip Inc, Xpan Inc, Saguaro Technologies, LifeEngine Technologies Inc and Ivano Bioscience. Over \$53,000 in cash and eight in-kind prizes were donated by sponsors: Pfizer, adMare BioInnovations, Fonds de solidarité FTQ, National Bank, Centech, Desjardins, MEDTEQ+, Investissement Québec, Amplitude Ventures, District 3, BioQuébec, CQIB, MedTech Canada, Oyster Venture Partners, CQDM and Fasken.



VISIBILITY

To ensure the organization's outreach in the LSHT sector and to achieve our strategic priorities, it is essential to rely on our communication channels and the messages they convey. Each year, our media presence expands, offering greater visibility to our many projects, our partners and ultimately, our mission.


The year 2022 was a milestone for Montréal InVivo, which reached **10,000 subscribers** on its LinkedIn page. This milestone reflects the growing visibility of our organization in the LSHT ecosystem and the numerous opportunities for mobilization, collaboration and dialogue that can result from Montréal InVivo's active presence on social media.

FIGURES AND STATISTICS

NEWSLETTERS 2022

78 NEWSLETTERS
+ 12 %
of newsletters

4,898 subscribers
to our newsletters




FIGURES AND STATISTICS

SOCIAL MEDIA 2022



THE PRESS





MOBILIZATION

As usual, the members of the Montréal InVivo team organized and participated in several events throughout the year. Whether on their own or in collaboration with their many partners, the activities organized in 2022 reflect the diversity and multidisciplinary strength of the sector in which the organization is actively involved.





B2B/2GO

In an effort to adapt to the hybrid business networking trends that have emerged in the context of the pandemic, Montréal InVivo has worked together with the B2B/2GO platform on several events in 2022. This collaboration aims to promote business networking within our organization, an essential lever for business development and ultimately, for the growth and promotion of Quebec and Canadian industries, know-how and economy.

PRESENCE OF THE CLUSTER'S STAKEHOLDERS


- Participants
- Private participants



380
meeting hours

3,448
total hours of participant
involvement

\$ CONTRIBUTION



DECISION-MAKERS

Alexandre Le Bouthillier
Linearis

Andrew Plank
Roche Diagnostics

Benoît Boulet
McGill University

Catherine Lunardi
GENAIZ

Cédric Bisson ☆
Teralys Capital Inc.

Christine Lennon
Incyte Biosciences

Dominique Bérubé
Concordia University

Fabrice Brunet
CHUM

Frank Béraud ☆
Chief Executive Officer
Montréal InVivo

Geneviève Guertin
Fonds de solidarité

Gordon McCauley
AdMare Bioinnovations

Jacques Milette
MEDTEQ+

Jean-Maurice Plourde
Honorary member

Marie-Ève Côté
ROBIC

Rémi Quirion
Fonds de recherche du Québec

Rhian Touyz
McGill Universit Health Centre

Véronique Bougie
Semathera

Yves Joannette
Université de Montréal

CHAIRMAN OF THE BOARD

Martin LeBlanc ☆
Caprion Biosciences Inc. / CellCarta


SECREYARY-TREASURER OF THE BOARD

Pierre Falardeau ☆
Consultation Pharma-Asset Inc.

VICE-CHAIR OF THE BOARD

Diane Gosselin ☆
Biopharmaceutical
Research Consortium

☆ Members of the Executive Committee



OUR TEAM

Known for being a passionate and collaborative team, the values and collective vision of Montréal InVivo's members facilitate our ability to rally around common goals and work together with the many LSHT industry players.

A HEART-FELT THANK YOU

The year 2022 was also marked by the departure of two true pillars of the organization, who were members of Montréal InVivo for over ten years: Nathalie Ouimet, Montréal InVivo's former Vice-President of Operations, and Diane Hubert, Executive Assistant and Corporate Affairs Coordinator for the organization, who celebrated her well-deserved retirement after a great career! Thank you both for your many years with the team and we wish you all the best for the future!

We also want to take this opportunity to thank Véronique Rochefort, Ève Labissière and Laurence Guilbault for their contribution to the team and their involvement in many projects in 2022, especially in communications and EFFERVESCENCE.

RENEWAL AT MONTRÉAL INVIVO

Despite a few departures, the Montréal InVivo team has nevertheless grown, with the arrival of five new members. The year 2022 represents a turning point for the organization, with a new dynamic team whose diverse backgrounds and profiles only enrich the projects in which we are involved.

THE TEAM'S MOST NOTABLE ACHIEVEMENTS IN 2022 AND
MOTIVATIONS FOR 2023



Alizée Gouronnec
Director – Business Development (SMEs) and Business Intelligence

2022 Achievement : Appreciated the work of students and post-doctoral fellows through the success of the first competition for popularizing scientific research projects in plain language at EFFERVESCENCE 2022.

2023 Motivation : Strengthen our relationships with SMEs in the sector to better identify their needs and increase our contribution to the development of Quebec’s entrepreneurial fabric.



Farah Bendahmane
Senior Director – Strategic Development and Partnerships

2022 Achievement : Montréal InVivo’s Strategic Plan on Rare Diseases unveiled.

2023 Motivation : Opportunities and challenges related to the new laws for access to health information and the redesign of the health system in Quebec.



Claudie Noël
Senior Director - Operations

2022 Achievement : The Continuum pilot project came to an end and the funding was established to ensure its continuity.

2023 Motivation : The growing team and the implementation of tools and collaboration to better support the ecosystem.



Robin Durand
Director - Integration of Innovation

2022 Achievement : Celebrated the 2022 EFFERVESCENCE Stars, rewarding collaborations between researchers and companies.

2023 Motivation : Develop concrete tools to encourage collaboration between the health network and innovators.



Frank Béraud
Chief Executive Officer

2022 Achievement : Montréal InVivo’s Strategic Plan on Rare Diseases was unveiled.

2023 Motivation : Develop new financial and business partnerships to support Montréal InVivo’s growth.



Laila Benameur ☆
Director - Entrepreneurship

2022 Achievement : An ecosystem mobilized to support promising start-ups during the EFFERVESCENCE pitch competition.

2023 Motivation : Value and support innovative entrepreneurs in LSHT.



Sophie Dallaire ☆
Project Manager – EFFERVESCENCE

2022 Achievement : New professional challenge: taking charge of producing EFFERVESCENCE 2023.

2023 Motivation : Strengthen EFFERVESCENCE's relevance in the Quebec life sciences ecosystem.



Aubrée Brodin ☆
Project Manager

2022 Achievement : Took on a new position at Montréal InVivo, after leaving clinical research.

2023 Motivation : Be increasingly involved in the various projects set up at Montréal InVivo and make the AI Health Podcast as widely known as possible throughout the sector.



Joëlle Chrisphonte ☆
Digital Communications Manager

2022 Achievement : Organized the first in-person «Ask the Expert» event.

2023 Motivation : Work with new tools to better understand and target our online community.



Inès Desanlis ☆
Project Manager

2022 Achievement : Left academic research to join Montréal InVivo and take on a new role in the ecosystem.

2023 Motivation : Set up an impactful project to promote collaboration between academic platforms and industries in the sector.



Malak Salah ☆
Communication and Marketing Manager

2022 Achievement : Start a first work experience in a new field.

2023 Motivation : Further develop Montréal InVivo's marketing focus to strengthen and promote the organization's visibility in the sector.

OUR ALLIES

2

HEALTHCARE
INSTITUTIONS

7

SUPPORT
ORGANIZATIONS

9

ACADEMIC
INSTITUTIONS

37

COMPANIES

OUR FINANCIAL PARTNERS



Abbvie
AstraZeneca Canada Inc.
Bausch Health, Canada Inc.
Boehringer Ingelheim Canada Ltd
Bristol-Myers Squibb Canada Co.
Gilead Sciences Canada, Inc.
GSK
Incyte Biosciences Canada
Janssen Pharmaceuticals, dba Johnson & Johnson
Merck Canada Inc.
Novartis Pharma Canada Inc.
Novo Nordisk Canada Inc.
Organon Canada Inc.
Pfizer
ROCHE
Teva Canadian Innovation

Vertex Pharmaceuticals (Canada) Inc.
CellCarta
CIRION Biopharma Recherche Inc.
IQVIA
Les laboratoires BNK Inc.
Mispro Biotech Services
Amgen Canada Inc.
Biogen
GENAIZ
Imagia Cybernetics Inc.
TELUS Solutions en santé Inc.
Amplitude Ventures
Entreprises AmorChem Inc.
Fiducie Alter Ego Le Bouthillier
Fonds de solidarité (FTQ)
Teralys Capital (Fonds d'Innovation) Inc.

Conseillers en gestion et informatique (CGI)
Fasken Martineau DuMoulin
Plakett Services Cliniques
Sectoral Asset Management
TACTIX
CERASP
École de technologie supérieure – ÉTS
The Research Institute of the McGill University Health Centre (RI-MUHC)
Institut national de la recherche scientifique – INRS
Institut National D'Optique (INO)
Polytechnique Montréal
Concordia University
McGill University
Université de Montréal

AdMare Bioinnovations
BIOQuébec
BioTalent
Consortium MEDTEQ+
Consortium de recherche biopharmaceutique (CQDM)
Médicaments novateurs Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal (CIUSSSCS)
National Research Council Canada (NRC)
Fonds de recherche du Québec-Santé (FRQS)

OUR COLLABORATORS

Aéro Montréal
AluQuébec
Aurora Cannabis
Axelys
B2B/2GO
BIOTECanada
BML Technology
Bureau du cinéma et de la télévision du Québec
Business France
CAE
CargoM
CATALIS Québec
Cégep G rald-Godin
CELS
Centech
Centre de recherche du CHUM
Centre d'expertise industrielle de Montr al

Chambre de commerce du Montr al m tropolitain
Clairvest
Coll ge Ahuntsic
Coll ge John-Abbott
Conseil national de recherches Canada
Consortium de recherche biopharmaceutique
Court Square Group
Desjardins
D veloppement  conomique Canada
Digifab QG
 cotech Qu bec
Emploi-Qu bec
Esplanade Qu bec
Finance Montr al
Gouvernement du Canada
Hacking Health

Institut national d'excellence en sant  et services sociaux
Innovation, Sciences et D veloppement  conomique Canada
Institut de recherches cliniques de Montr al
Institut TransMedTech
Investissement Qu bec
Institut de recherche en immunologie et en cancérologie
IRICoR
IVADO
John Molson School of Business
KAKEE
KPMG Canada
Le R seau Mentorat
Les Offices jeunesse internationaux du Qu bec

Mila
Mispro Biotech
Montr al International
Ontario Bioscience Innovation Organization
Organon
Pangea Consultants
PME Montr al
Prompt
Propulsion Qu bec
Qualifications Qu bec
Quartier de l'innovation en sant 
SAGE Innovation
Services Qu bec
Sherbrooke Innopole
TACT
TechnoMontr al/NUMANA
Universit  du Qu bec   Montr al

MAACS Biopharma Consulting
Medtech Canada
Minist re de la Sant  et des Services sociaux du Qu bec
Mmode
Montr al International
Ordre des chimistes du Qu bec
OROKOM
Palais des congr s de Montr al
Paraza Pharma
Pharmabio D veloppement
Polytechnique Montr al
ROBIC
Soci t  de recherche sur le cancer
Ville de Laval



630 Sherbrooke Street West, Suite 460
Montréal, Québec H3A 1E4
514 987-9377
montreal-invivo.com

